Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: Interim results from an ongoing phase 1 study von Yu, Helena Alexandra, Spira, Alexander I., Horn, Leora, Weiss, Jared, West, Howard Jack, Giaccone, Giuseppe, Evans, Tracey L., Kelly, Ronan Joseph, Desai, Bhardwaj B., Krivoshik, Andrew, Fleege, Tanya E., Poondru, Srinivasu, Jie, Fei, Aoyama, Kouji, Whitcomb, Debbie Ann, Keating, Anne Therese, Oxnard, Geoffrey R.

Volltext